Literature DB >> 30404861

68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging.

Jianquan Yang1, Jingli Xu1, Rene Gonzalez2, Thomas Lindner3, Clemens Kratochwil4, Yubin Miao5.   

Abstract

Melanocortin-1 receptor (MC1R) is a molecular target for melanoma imaging and therapy because of its overexpression on rodent and human melanoma cells. Here, we evaluated the MC1R targeting and specificity of 68Ga-DOTA-GGNle-CycMSHhex and Cy5.5-GGNle-CycMSHhex using murine and human melanoma cells, and murine and xenografted tumors. 68Ga-DOTA-GGNle-CycMSHhex was used first in human as an imaging probe to evaluate the possibility of radionuclide therapy in patients with advanced-stage melanoma. 68Ga-DOTA-GGNle-CycMSHhex and Cy5.5-GGNle-CycMSHhex displayed MC1R-specific targeting properties in murine and human melanoma cells, as well as in murine melanoma and human melanoma-xenografted tumors. Both B16/F10 and M21 melanoma lesions could be easily imaged by positron emission tomography using 68Ga-DOTA-GGNle-CycMSHhex The first-in-human images of melanoma brain metastases in patients demonstrated the clinical relevance of MC1R as a molecular target for melanoma imaging, highlighting the potential of 68Ga-DOTA-GGNle-CycMSHhex as an MC1R-targeting melanoma imaging probe and underscoring the need to develop MC1R-targeting therapeutic agents for treating patients with metastatic melanoma.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30404861      PMCID: PMC6383514          DOI: 10.1126/scitranslmed.aau4445

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  40 in total

1.  99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection.

Authors:  Yubin Miao; Katherine Benwell; Thomas P Quinn
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 3.  Treatment of metastatic malignant melanoma.

Authors:  Ehab Atallah; Lawrence Flaherty
Journal:  Curr Treat Options Oncol       Date:  2005-05

4.  Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma.

Authors:  Haixun Guo; Yubin Miao
Journal:  J Nucl Med       Date:  2014-11-07       Impact factor: 10.057

5.  Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Yubin Miao
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

6.  Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake.

Authors:  Haixun Guo; Jianquan Yang; Fabio Gallazzi; Yubin Miao
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

7.  Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.

Authors:  Haixun Guo; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2013-02-24       Impact factor: 2.823

8.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

9.  Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide.

Authors:  Han Jiang; Benjamin B Kasten; Hongguang Liu; Shibo Qi; Yang Liu; Mei Tian; Charles L Barnes; Hong Zhang; Zhen Cheng; Paul D Benny
Journal:  Bioconjug Chem       Date:  2012-11-08       Impact factor: 4.774

10.  In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy.

Authors:  Yubin Miao; Nellie K Owen; Donna Whitener; Fabio Gallazzi; Timothy J Hoffman; Thomas P Quinn
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

View more
  12 in total

1.  Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting.

Authors:  Jianquan Yang; Jingli Xu; Lina Cheuy; Rene Gonzalez; Darrell R Fisher; Yubin Miao
Journal:  Mol Pharm       Date:  2019-02-25       Impact factor: 4.939

2.  Novel [99mTc]-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake.

Authors:  Zheng Qiao; Jingli Xu; Rene Gonzalez; Yubin Miao
Journal:  Mol Pharm       Date:  2020-07-28       Impact factor: 4.939

3.  Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide.

Authors:  Jingli Xu; Jianquan Yang; Rene Gonzalez; Darrell R Fisher; Yubin Miao
Journal:  Cancer Biother Radiopharm       Date:  2019-10-23       Impact factor: 3.099

4.  Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles.

Authors:  Xiuli Zhang; Feng Chen; Melik Z Turker; Kai Ma; Pat Zanzonico; Fabio Gallazzi; Manankumar A Shah; Austin R Prater; Ulrich Wiesner; Michelle S Bradbury; Michael R McDevitt; Thomas P Quinn
Journal:  Biomaterials       Date:  2020-02-19       Impact factor: 12.479

5.  A tumor-targeted immune checkpoint blocker.

Authors:  Yuhan Zhang; Changming Fang; Rongsheng E Wang; Ying Wang; Hui Guo; Chao Guo; Lijun Zhao; Shuhong Li; Xia Li; Peter G Schultz; Yu J Cao; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-22       Impact factor: 11.205

6.  The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of 67Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides.

Authors:  Jingli Xu; Fabio Gallazzi; Darrell R Fisher; Rene Gonzalez; Yubin Miao
Journal:  Cancer Biother Radiopharm       Date:  2021-11-11       Impact factor: 3.099

7.  Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting.

Authors:  Jingli Xu; Zheng Qiao; Rene Gonzalez; Yubin Miao
Journal:  Bioorg Med Chem Lett       Date:  2020-10-24       Impact factor: 2.823

Review 8.  Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.

Authors:  Natalie J Serkova; Kristine Glunde; Chad R Haney; Mohammed Farhoud; Alexandra De Lille; Elizabeth F Redente; Dmitri Simberg; David C Westerly; Lynn Griffin; Ralph P Mason
Journal:  Cancer Res       Date:  2020-12-01       Impact factor: 13.312

Review 9.  Insight into the Development of PET Radiopharmaceuticals for Oncology.

Authors:  Joseph Lau; Etienne Rousseau; Daniel Kwon; Kuo-Shyan Lin; François Bénard; Xiaoyuan Chen
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

10.  Selective Cyclized α-Melanocyte-Stimulating Hormone Derivative with Multiple N-Methylations for Melanoma Imaging with Positron Emission Tomography.

Authors:  Chengcheng Zhang; Zhengxing Zhang; Jutta Zeisler; Nadine Colpo; Kuo-Shyan Lin; François Bénard
Journal:  ACS Omega       Date:  2020-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.